News

HuMy9-6-DM4, a tumor-activated prodrug (TAP) compound, comprises the engineered antibody huMy9-6, which binds specifically to the CD33 target found on acute myeloid leukemia cancer cells, and DM4, a

For the first time in this disease area, researchers at the Serono Genetics Institute (SGI) have identified 80 genes involved in the inflammatory and neuro-degenerative pathways of multiple

Predix will receive up to $12.5 million in milestone-driven funds over the next three years through a therapeutics development award from Cystic Fibrosis Foundation Therapeutics (CFFT). The award

The newly approved agent will be marketed in the US under the name Mycamine (micafungin sodium for injection). The approval is based on 32 clinical studies conducted in

Symlin (pramlintide acetate) injection will be used at mealtime in patients with type 2 or type 1 diabetes who have failed to achieve desired glucose control despite optimal

The approval was based on data that demonstrated a significant overall survival benefit in patients who were treated with Temodar(temozolomide) in combination with radiotherapy. Concurrent with the approval

The company’s clinical program for AMD070 is being conducted by leading investigators at the US Adult AIDS Clinical Trials Group (ACTG), which is supported by the National Institute

In the expanded partnership, OncoGenex will be solely responsible for the preclinical and clinical development of the added anticancer drugs. OncoGenex will pay Isis an upfront fee, milestone

The National Cancer Institute (NCI) findings in osteosarcoma, a form of bone cancer, are consistent with a preclinical study of CTCE-9908 conducted by researchers at Chemokine Therapeutics. CTCE-9908